DEF: Neurocrine Biosciences Sets May 27 Annual Meeting

Neurocrine Biosciences, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 27, 2026, to vote on director elections, executive compensation, equity plan amendments, and auditor ratification.

Summary

• Neurocrine Biosciences, Inc. is holding its 2026 Annual Meeting of Stockholders on May 27, 2026, at its corporate offices in San Diego, California.
• Key agenda items include the election of three Class III directors, an advisory vote on executive compensation, approval to amend the 2025 Equity Incentive Plan to increase share reserve by 4,000,000 shares, and ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.
• Stockholders of record as of March 31, 2026, are entitled to vote.
• The company encourages stockholders to vote by proxy via internet, telephone, or mail, rather than attending in person.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting standard corporate governance and compensation practices with a focus on long-term alignment and talent retention, while also acknowledging past clinical trial setbacks.

Positives

• The company is seeking to increase its equity incentive plan by 4,000,000 shares to continue attracting and retaining talent.
• The Board of Directors is composed of individuals with strong backgrounds in executive leadership, capital management, scientific research, and drug development.
• All current directors, except for the CEO and former CEO, meet the Nasdaq independence standards.
• The company has a director resignation policy for nominees receiving less than majority support.
• The company has a robust corporate governance framework, including a separate Chairman and CEO, a clawback policy, and an overboarding policy.
• The Compensation Committee concluded that the company's compensation policies and practices do not create risks that are reasonably likely to have a material adverse effect on the company.
• The company has strong equity ownership guidelines for executives and directors, with all officers in compliance as of March 31, 2026.
• The company has a policy prohibiting hedging, pledging, or margining of company stock by directors, officers, and employees.
• The company has a compensation recoupment policy in place.
• The company's executive compensation program is designed to pay for performance, with a significant portion of pay being at-risk.
• The company's say-on-pay advisory vote results have historically been strong, with approximately 91% approval in 2025.
• The company has a clear compensation philosophy focused on attracting, motivating, and retaining executive talent, incentivizing long-term stockholder value, and maximizing stockholder value.
• The company has implemented changes to its executive compensation program for 2025, including a standardized equity award mix and increased target annual cash incentive opportunities for NEOs (excluding the CEO).
• The company has an Executive Severance Plan adopted in February 2025.
• The company's non-employee director compensation philosophy aligns director interests with stockholders, with a heavy weighting towards equity.
• The company's non-employee directors are in compliance with equity ownership guidelines as of March 31, 2026.

Negatives

• The company's Phase 3 studies of valbenazine in schizophrenia and dyskinesia due to cerebral palsy (DCP) did not meet their primary endpoints.
• The company's Phase 2 study of NBI-770 in major depressive disorder (MDD) did not meet its primary endpoint.
• One report for each of Kyle Gano, Matt Abernethy, Darin Lippoldt, Julie Cooke, Eiry Roberts, David Boyer, Eric Benevich, and Kevin Gorman was inadvertently filed one business day late due to an administrative oversight.

Risks

• The company's Phase 3 studies of valbenazine in schizophrenia and dyskinesia due to cerebral palsy (DCP) did not meet their primary endpoints.
• The company's Phase 2 study of NBI-770 in major depressive disorder (MDD) did not meet its primary endpoint.
• The company's stock options and other equity awards are subject to market volatility and may not provide value if the stock price does not appreciate.
• The company's business is subject to the risks and uncertainties inherent in the development and commercialization of pharmaceutical products, including clinical trial results, regulatory approvals, and market acceptance.
• The company's future success depends on its ability to successfully develop and commercialize its product candidates, which is subject to significant risks and uncertainties.
• The company's reliance on third-party manufacturers for its products could impact its ability to supply its products.
• The company faces intense competition from other pharmaceutical and biotechnology companies.
• The company's ability to protect its intellectual property is critical to its success.
• The company's operations are subject to extensive government regulation, and changes in regulatory requirements could adversely affect its business.
• The company's ability to attract and retain qualified personnel is essential for its success.
• The company's financial performance may be adversely affected by economic conditions.
• The company's stock price may be volatile and subject to fluctuations.
• The company's ability to manage its growth and expansion effectively is crucial for its long-term success.

Future Outlook

The company is seeking to increase its equity incentive plan by 4,000,000 shares to support its ongoing talent acquisition and retention efforts, anticipating a need for additional shares in 2027.

Management Comments

• We believe that our directors hold themselves to the highest standards of integrity and that they are committed to representing the long-term interests of our stockholders.
• We believe that our directors varied backgrounds and experiences result in different perspectives, ideas, and viewpoints, which make our Board more effective in carrying out its duties.
• The Board and the Nominating / Corporate Governance Committee will periodically review and continue to consider whether the classified Board structure aligns with the Companys long-term strategic objectives.
• The Compensation Committee concluded that the Companys compensation policies and practices are consistent with industry practices for similar biopharmaceutical companies and do not create risks that are reasonably likely to have a material adverse effect on the Company.
• We believe that the grant of equity awards is a key element underlying our ability to attract, retain and motivate our employees, directors and consultants because of the strong competition for highly trained and experienced individuals among biopharmaceutical companies.
• We believe that the Amended 2025 Plan is in the best interests of our business and our stockholders and unanimously recommends a vote in favor of this Proposal Three.
• We believe the use of equity awards strongly aligns the interests of our employees with those of our stockholders by placing a considerable proportion of our employees total compensation at risk because it is contingent on the appreciation in value of our common stock.
• We believe equity awards encourage employee ownership of our common stock and promote retention through the reward of long-term Company performance.
• We carefully manage the use of equity awards and dilution is reasonable.
• The Board of Directors believes that the separation of the Board of Directors and Company leadership reinforces the independence of the Board of Directors in its oversight of the business and affairs of the Company, and creates an environment that is more conducive to objective evaluation and oversight of management's performance, increasing management accountability and improving the ability of the Board of Directors to monitor whether management's actions are in the best interests of the Company and its stockholders.

Industry Context

StockSavvy.ai notes that Neurocrine Biosciences' focus on neurological, psychiatric, endocrine, and immunological disorders places it within a competitive but high-growth segment of the biopharmaceutical industry. The proposed increase in the equity incentive plan aligns with industry practices for attracting and retaining specialized talent in this sector.

Corporate Governance

Related Party Transactions

• There were no related party transactions during fiscal year 2025.

Stakeholder Impact

• Stockholders will have the opportunity to vote on key corporate matters, influencing the composition of the Board and executive compensation practices.
• Employees may benefit from the proposed increase in the equity incentive plan, which is intended to attract, retain, and motivate talent.
• The company's commitment to corporate responsibility and ethical business practices is highlighted, potentially impacting community and stakeholder perception.

Next Steps

• Stockholders are encouraged to submit their proxy votes by internet, telephone, or mail.
• The company will announce preliminary voting results at the Annual Meeting.
• Final voting results will be published in a Form 8-K filed with the SEC within four business days after the Annual Meeting.

Key Dates

Recommendation

The filing outlines standard annual meeting procedures and proposals. While the company demonstrates strong corporate governance and a pay-for-performance compensation philosophy, the mention of recent clinical trial setbacks in key areas suggests a need for caution. The proposed equity plan increase is a positive for talent management, but without new financial performance data or significant strategic shifts, a 'hold' recommendation is appropriate pending further developments.

Keywords

Neurocrine Biosciences, Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Equity Incentive Plan, Ernst & Young LLP, Director Election, Corporate Governance